ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology,
Inc., a precision oncology company advancing molecular indications
for cancer therapies, today announced it has signed an agreement
with Mirati Therapeutics, Inc. (NASDAQ:MRTX) to broaden patient
identification and enrollment for Mirati's Phase 1/2 study of
MRTX849 in patients with cancer having a KRAS G12C mutation
(clinicaltrials.gov identifier: NCT03785249). The multiple
expansion cohort study will evaluate the safety, tolerability, drug
levels, molecular effects, and clinical activity of MRTX849 in
patients with advanced solid tumors who have a KRAS G12C
mutation.
Under the terms of the agreement and through the Strata Trial,
Strata Oncology will identify patients with advanced solid tumors
who have a KRAS G12C mutation and meet other eligibility criteria,
to be considered for enrollment into Mirati's Phase 1/2 study,
MRTX849-001 a G12C selective inhibitor. The Strata Trial, an
ongoing observational study providing tumor molecular profiling for
patients with advanced cancer paired with a portfolio of
biomarker-guided clinical trials, is available across a network of
20+ select health systems nationwide. Through the Strata Trial,
patients with advanced cancer are profiled using
StrataNGSTM, a comprehensive molecular profiling test
optimized for performance on tumor tissue samples as small as
0.5mm2 surface area.
"Our partnership with Mirati Therapeutics is reflective of our
shared goal to develop new medicines not by tissue type but by
molecular profile, producing superior outcomes for patients and
potentially faster drug approvals," said Dan Rhodes, Ph.D., CEO of Strata Oncology. "We
are confident our network of health systems, standardized on the
Strata Trial, will bring additional support to help broaden
enrollment of this important clinical trial."
For more information about the trial, please visit
https://clinicaltrials.gov/ct2/show/NCT03785249
About Strata Oncology
Strata Oncology, Inc. is a precision medicine company dedicated
to transforming cancer care by building a platform to systematize
precision oncology across a network of health systems and biopharma
companies. Strata Oncology empowers health systems to deliver a
comprehensive, system-wide precision oncology program that
integrates cutting-edge tumor molecular profiling and a portfolio
of biomarker-guided with routine care, so that all patients with
advanced cancer have the opportunity to benefit. This large network
of trial-ready health systems provides a mechanism to rapidly and
predictably enroll precision therapy trials. For more information
visit www.strataoncology.com.
Strata Inquiries:
Terri Clevenger
(203) 856-4326
Terri.clevenger@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/strata-oncology-announces-partnership-to-broaden-enrollment-in-mirati-therapeutics-clinical-trial-of-mrtx849-a-novel-kras-g12c-selective-inhibitor-301111460.html
SOURCE Strata Oncology, Inc.